Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
11 avr. 2024 08h05 HE
|
Tevogen Bio Inc
Tevogen’s Chief Scientific Officer explains the company’s oncology pipeline strategy as it relates to harnessing Cytotoxic T Lymphocytes to target cancers.
[Latest] Global Pet Cancer Therapeutics Market Size/Share Worth USD 1,162.4 Million by 2033 at a 9.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
08 avr. 2024 13h30 HE
|
Custom Market Insights
Austin, TX, USA, April 08, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Pet Cancer Therapeutics Market Size, Trends and Insights By Therapy...
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
03 avr. 2024 07h00 HE
|
ADC Therapeutics SA
LAUSANNE, Switzerland, April 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company will host a virtual Research Investor Event on Tuesday, April 9, 2024,...
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
01 avr. 2024 16h05 HE
|
ADC Therapeutics SA
LAUSANNE, Switzerland, April 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (the “Company”) (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of...
Hemato Oncology Testing Market Anticipated to Surge Amid Technological Innovations and Increased Cancer Prevalence
22 janv. 2024 21h23 HE
|
Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Hemato Oncology Testing Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The latest comprehensive research on...
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
11 déc. 2023 07h00 HE
|
Marker Therapeutics
HOUSTON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Oncology Based In-Vivo CRO Industry Experiences Surge with Innovative Solutions: Global Market Report 2023 Explores Trends and Growth Factors
11 déc. 2023 04h28 HE
|
Research and Markets
Dublin, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The "Oncology Based In-Vivo CRO Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global market for...
Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial
08 déc. 2023 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
CARGO Therapeutics Announces Pricing of Initial Public Offering
09 nov. 2023 20h07 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Announce Pricing of IPO
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
09 nov. 2023 17h00 HE
|
Marker Therapeutics
Announced complete response in first patient with lymphoma treated with MT-601 in Phase 1 APOLLO trial following CAR T relapse Received Orphan Drug Designation (ODD) from European Medicines Agency...